Tag
This study evaluates adherence to NCCN guidelines and taper durations of corticosteroids in managing severe immune-related adverse events (irAEs) among gynecologic cancer patients receiving immune checkpoint inhibitors, revealing that guide
The Chinese Society of Colorectal Surgery consensus (Gut 2026) standardizes use of immune checkpoint inhibitors (ICIs) in locally advanced rectal cancer—diagnostics, perioperative strategies, organ preservation, safety and follow-up.
A randomized trial shows that a 6-week corticosteroid taper is superior to a 3-week taper for mild immune-related pneumonitis, establishing 6 weeks as the evidence-based standard for short-term treatment success.
This review synthesizes recent evidence on immune checkpoint inhibitor (ICI)-based downstaging therapy for hepatocellular carcinoma (HCC) beyond Milan criteria prior to liver transplantation, highlighting improved oncologic outcomes alongsi
This study evaluates the safety and clinical outcomes of immune checkpoint inhibitor rechallenge in classical Hodgkin lymphoma patients following immune-related adverse events, demonstrating feasibility and preserved efficacy in selected ca
This longitudinal study reveals that gut microbiome remodeling during immune checkpoint inhibitor therapy in advanced liver cancer patients predicts clinical benefit, improving biomarker accuracy and survival stratification.
This study reveals that immune checkpoint and VEGF inhibitors, alone or combined, do not induce detectable arterial inflammation by PET, suggesting macrophage-driven plaque activation is not the main cause of related atherothrombotic events
A phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.
Circulating extracellular vesicles carrying PD-1, PD-L1, and CTLA-4 can non-invasively predict responses and early resistance to immune checkpoint inhibitors in advanced hepatocellular carcinoma, improving patient stratification and managem
This study analyzes real-world data showing that MLH1 promoter hypermethylation and Lynch syndrome-associated genetic mutations confer similar response rates and survival outcomes in mismatch repair deficient endometrial cancer treated with
This study uncovers a novel DR5/Ligase 3 feedback mechanism that sustains immunogenicity and enhances immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer.
A multicenter study found that immune checkpoint inhibitor–associated uveitis risk varies by cancer type and drug class, with melanoma showing the highest intrinsic risk and RCC risk largely linked to ipilimumab/nivolumab exposure.
This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.
A Gut study identifies MLCK1-driven epithelial barrier failure as a central mechanism in immune checkpoint inhibitor colitis and suggests epicatechin as a barrier-protective strategy that preserves antitumour efficacy in preclinical models.
This study identifies CXCR6+ T cells as the primary drivers of immune checkpoint inhibitor-induced myocarditis, especially with anti-LAG-3/PD-1 combinations. Researchers demonstrate that targeting the CXCR6-CXCL16 axis can reduce cardiac in
A prospective multicenter study of 433 patients demonstrates that combining stereotactic radiotherapy with biological cancer therapy is safe, with severe adverse events occurring in less than 10% of cases. Crucially, continuing biological t
A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial ex
A patient‑level and trial‑level meta‑analysis of nine RCTs (5,114 patients) shows that adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves pathologic complete response and event‑free survival in triple‑negative breast c
An expert summary of the 2025 ICS position statement on immune checkpoint inhibitor–associated cardiovascular toxic effects, with practical diagnostic and treatment guidance for clinicians and researchers.
An international cohort of 2,052 NSCLC patients with leptomeningeal disease shows rising prevalence and improved survival in the modern treatment era. CNS‑penetrant tyrosine kinase inhibitors and immune checkpoint inhibitors are key drivers
